The company moved to increase the scale of its offering to 3.75 million shares, surpassing the original target of 3.3 million shares. By setting the price at $12, the firm navigated a range that had previously fluctuated between $11 and $13. Retension Pharmaceuticals will trade under the ticker symbol RTSN on the Nasdaq Capital Market as it shifts from a private clinical-stage entity to a publicly listed organization.
Retension Pharmaceuticals Prices IPO at $45 Million
Clinical-stage firm Retension Pharmaceuticals enters the public market Friday, locking in a $45 million valuation after finalizing its upsized initial public offering. The Falls Church-based company settled on a $12 share price, landing exactly at the midpoint of its projected range as it prepares for its Nasdaq debut.
When reusing this material a link to Money Talk is required.
Comments (0)
No comments yet. Be the first!